Sinotau Pharmaceutical Group
Clinical trials sponsored by Sinotau Pharmaceutical Group, explained in plain language.
-
Radioactive drug shows promise in slowing advanced gut tumors
Disease control OngoingThis phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high-dose standard drug (Octreotide LAR) in 196 adults with advanced neuroendocrine tumors that could not be removed by surgery. The goal was to see which treatment better delayed tumor growt…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
New radioactive treatment shows promise for Hard-to-Treat tumors
Disease control OngoingThis study tests a radioactive drug (Lutetium-177) in 74 adults with advanced neuroendocrine tumors that cannot be removed by surgery and have gotten worse. The goal is to see if the drug is safe and can shrink or control the tumors. Participants receive the drug and are monitore…
Phase: PHASE2, PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated May 17, 2026 04:32 UTC